Karyopharm Therapeutics (NASDAQ:KPTI) Price Target Lowered to $54.00 at Robert W. Baird

Karyopharm Therapeutics (NASDAQ:KPTI) had its price target lowered by Robert W. Baird from $75.00 to $54.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has an outperform rating on the stock.

Other research analysts also recently issued research reports about the company. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $45.00 price objective on shares of Karyopharm Therapeutics in a research note on Thursday, February 20th. Piper Sandler increased their target price on Karyopharm Therapeutics from $60.00 to $75.00 and gave the stock an “overweight” rating in a research report on Wednesday, November 6th. StockNews.com cut Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, November 22nd. Finally, HC Wainwright increased their target price on Karyopharm Therapeutics from $7.00 to $56.00 and gave the stock a “buy” rating in a research report on Wednesday, February 26th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, Karyopharm Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Karyopharm Therapeutics Stock Performance

KPTI stock opened at $7.25 on Monday. Karyopharm Therapeutics has a fifty-two week low of $7.14 and a fifty-two week high of $25.50. The business’s 50-day moving average is $9.81 and its two-hundred day moving average is $11.24. The company has a market cap of $61.05 million, a price-to-earnings ratio of -7.11 and a beta of 0.06.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Wednesday, February 19th. The company reported ($3.60) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.90) by $0.30. The firm had revenue of $30.54 million during the quarter, compared to the consensus estimate of $30.29 million. Equities analysts predict that Karyopharm Therapeutics will post -0.71 earnings per share for the current year.

Hedge Funds Weigh In On Karyopharm Therapeutics

A number of large investors have recently bought and sold shares of KPTI. Adage Capital Partners GP L.L.C. boosted its holdings in Karyopharm Therapeutics by 46.3% during the 4th quarter. Adage Capital Partners GP L.L.C. now owns 6,319,842 shares of the company’s stock valued at $4,274,000 after acquiring an additional 2,000,000 shares during the period. GSA Capital Partners LLP boosted its holdings in Karyopharm Therapeutics by 80.6% during the 3rd quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company’s stock valued at $1,474,000 after acquiring an additional 792,283 shares during the period. Jane Street Group LLC boosted its holdings in Karyopharm Therapeutics by 265.5% during the 4th quarter. Jane Street Group LLC now owns 748,306 shares of the company’s stock valued at $506,000 after acquiring an additional 543,556 shares during the period. Marshall Wace LLP boosted its holdings in Karyopharm Therapeutics by 15.3% during the 4th quarter. Marshall Wace LLP now owns 2,401,413 shares of the company’s stock valued at $1,633,000 after acquiring an additional 319,187 shares during the period. Finally, Shay Capital LLC purchased a new position in Karyopharm Therapeutics during the 4th quarter valued at $116,000. Hedge funds and other institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).